速百纳斯制药

最新新闻

• 评级变动
  Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $67
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• 评级变动
  Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $66
  \u5e02\u573a\u8d44\u8baf · 2026/4/13
• 评级变动
  Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $63
  \u5e02\u573a\u8d44\u8baf · 2026/1/9
• 评级变动
  Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $63
  \u5e02\u573a\u8d44\u8baf · 2025/9/30
• Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $66
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 公司公告
  Supernus Pharmaceuticals: Supernus Pharmaceuticals, Inc. - Anticipated Adjustment Option Symbol: SUPN New Symbol: SUPN1
  OCC · 2026/9/17
• 评级变动
  TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• 评级变动
  TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2025/11/5
• Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, Vs. FactSet Est of $0.04 EPS
  MT Newswires · 2026/8/3
• 评级变动
  Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/1/28
• 评级变动
  Piper Sandler Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2025/10/9
• BofA Securities Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $63
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $43
  \u5e02\u573a\u8d44\u8baf · 2025/8/7
• 评级变动
  BofA Securities Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• 评级变动
  Cantor Fitzgerald Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2025/7/30
• 评级变动
  Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2025/12/19
• TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2025/10/23
• Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q2 Revenue $219.1M, Vs. FactSet Est of $205.3M
  MT Newswires · 2026/8/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。